A. Mims, Zhuoer Xie, A. Vasconcelos, M. Strocchia, Willem Heydendael, M. Chevli, D. Rotter, R. Potluri, T. Prebet, J. Sieluk
{"title":"以口服阿扎胞苷(Oral- aza)作为维持治疗的急性髓性白血病(AML)患者与符合但未在美国电子健康记录(EHR)数据库中接受治疗的患者AML-068生存差异","authors":"A. Mims, Zhuoer Xie, A. Vasconcelos, M. Strocchia, Willem Heydendael, M. Chevli, D. Rotter, R. Potluri, T. Prebet, J. Sieluk","doi":"10.1016/s2152-2650(23)00411-1","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":10370,"journal":{"name":"Clinical Lymphoma Myeloma and Leukemia","volume":"83 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"POSTER: AML-068 Survival Differences in Patients With Acute Myeloid Leukemia (AML) Treated With Oral Azacitidine (Oral-AZA) as Maintenance and Those Eligible but Not Treated in a US Electronic Health Record (EHR) Database\",\"authors\":\"A. Mims, Zhuoer Xie, A. Vasconcelos, M. Strocchia, Willem Heydendael, M. Chevli, D. Rotter, R. Potluri, T. Prebet, J. Sieluk\",\"doi\":\"10.1016/s2152-2650(23)00411-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":10370,\"journal\":{\"name\":\"Clinical Lymphoma Myeloma and Leukemia\",\"volume\":\"83 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Lymphoma Myeloma and Leukemia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/s2152-2650(23)00411-1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma Myeloma and Leukemia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s2152-2650(23)00411-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
POSTER: AML-068 Survival Differences in Patients With Acute Myeloid Leukemia (AML) Treated With Oral Azacitidine (Oral-AZA) as Maintenance and Those Eligible but Not Treated in a US Electronic Health Record (EHR) Database